MedTrace Logo

Evaluation of the IPS System for TLD Therapy in Patients With COPD

NCT01716598 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2016-09-23

No results posted yet for this study

Summary

Targeted Lung Denervation (TLD) Therapy will be a safe method to ablate the airway nerve trunks that travel parallel to and outside of the main bronchi and into the lungs to achieve targeted lung denervation and potentially improve breathing and quality of life for patients suffering from COPD.

Use of the IPS System will be technically feasible in accessing the target treatment location and delivering RF energy to the target treatment location.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DEVICE

IPS System

TLD Therapy will be achieved bronchoscopically.

Sponsors & Collaborators

  • Nuvaira, Inc.

    lead INDUSTRY

Principal Investigators

  • Arschang Valipour, MD, FCCP, Ass. Prof. · Otto-Wagner Hospital, Vienna, Austria

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-10-31
Primary Completion
2014-05-31
Completion
2016-04-30

Countries

  • Austria
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01716598 on ClinicalTrials.gov